B2C-Brands-Bone&Joints

Jointcore^® is a novel synergistic formula for comprehensive management of arthritis. It offers three ingredients (Natural Egg Shell Membrane (NESM)^® , AKBACORE^® AKKBA (Acetyl-11-keto-beta-boswellic acid (30% AKKBA) and CUMINCORE,^®. AKBACORE^®   act via different pathways to offer symptomatic relief; reducing pain, inflammation and joint stiffness and increasing mobility. NESM works as biogenic precursor to fix the body damage of collagen, cartilage and synovial fluids. NESM also fixes the faults in the immune system to reduce cartilage destruction and helps in joint lubrication, reduces synovial effusion and synovial inflammation and increases muscle strength, Boswellin Super prevents formation of inflammatory mediators to reduce pain and inflammation and also prevents cartilage destruction.

•                                                               

  MUTTAIJOW COMPLEX® * Biogenic precursor to fix cartilage damages * Suppression of TNF-α  IFN-γ * Reduced levels of IL-6, IL-10  * Activate level of nuclear factor kappa-light-chain-enhancer of activated B cells.

  AKBACORE ® * CO Inhibitor

  CUMINCORE ® * LO Inhibitor

  Medical Journal Publications

  A randomized, open‑label, multicentered parallel‑group clinical study to evaluate the efficacy and safety of Joint Core TM (Natural Eggshell Membrane [MuttaiJow Complex TM] 400 mg + Akbacore TM Boswellia serrata [30% Akba] 90 mg + Cumincore TM [curcumin extract 96%] 10 mg) compared to Jointace DN TM (glucosamine 750 mg + diacerein 50 mg + methylsulfonylmethane 250 mg) in osteoarthritis patients  2022 Journal of Current Research in Scientific Medicine | Published by Wolters Kluwer  Medknow jcrsm_21_22_R2_OA 10.4103/jcrsm.jcrsm_21_22

   

  results of clinical studies

  Pain management is much better and early with Joint Core ^®  as per the comparative data on PAIN VAS SCALE, WOMAC PAIN SUB SCALE, GLOBAL ASSESSMENT ON IMPROVEMENTS ON OSTEO ARTHRITIS SCORE, OMERACT-OARSI. Thus Nutraceuticals Combinations of  Joint Core^®  has proved to be equivalent to that of the reference Drug  combinations of  Jointace DN in the management of Osteoarthritis patients by reducing inflammation, providing adequate pain relief and improving the patients functional capacity, without causing any major side effects or drug interactions as it is obtained from natural sources.

  • Joint Core^®  reduce  Sr Creatinine values by 25 %  from 1.1 (+/- ) 1.0 at zero day  to 0.83 (+/-) 0.19 in 12 weeks.

  • Joint Core^® has Anti-inflammatory activity to CONTROL the HS- CRP inflammatory markers from o day at 7.15 (+/- ) 4.6 to 3.86 (+/- ) 2.91 in 12 weeks

  • Joint Core^®  has Anti-inflammatory activity to CONTROL the ESR inflammatory markers from o day at 45.75 (+/- ) 32.83 to 9.0 (+/- ) 4.5 in 12 weeks

  • Joint Core^® has Inflammatory markers: Fibrinogen Levels from 0 day at 309.29 (+/- ) 96.31 to 9.0 (+/- ) 4.5 in 12 weeks.

  • Joint Core^® has shown significant improvement in Osteoarthritis patients with respect to the management of pain, reduction of inflammatory markers and functional
    improvement.

  • Joint Core^® , has proved to be a good natural supplement for taking care of Joint pain, joint stiffness and thereby improving the joint flexibility and mobility in Osteoarthritis patients. The Test product, Joint Core^® (Natural egg shell membrane (Muttai Jow Complex^® ) 400 mg + ABKACORE^®  Boswellia serrata (30%AKBA) 90 mg + CUMINCORE^® (Curcumin extract96%) 10 mg) has shown significant improvement in Osteoarthritic patients with respect to the management of pain, reduction of inflammatory markers and functional improvement.

  • Thus, the test product Joint Core^®  has proved to be equivalent to that of the reference product Jointace DN in the management of Osteoarthritis patients by reducing inflammation, providing adequate pain relief and improving the patients functional capacity, without causing any major side effects or drug interactions as it is obtained from natural sources. Thus, Joint Core^® , has proved to be a good natural supplement for taking care of Joint pain, joint stiffness and thereby improving the joint flexibility and mobility in Osteoarthritic patients.

  • The first line pharmacological therapy for Osteoarthritis consists of topical or oral non-steroidal anti-inflammatory drugs (NSAIDS) which only provide symptomatic pain relief and it is associated with serious life time risk after prolonged use. However continuous usage of NSAIDs can increase the chance of heart attack or stroke with higher doses or with long-term use. It is very uncertain that the patients are not aware about the fundamental difference between the effects on short term prescribed drugs vs. the long term prescribed drugs. Such lack of awareness makes OA patients dependent on the unethical practice or self practice of drugs and makes their life miserable over the period of time with severe damages on Liver and Kidney.

  • Mechanism of Action